Commentary
Video
Author(s):
Nikhil I. Khushalani, MD, of Moffitt Cancer Center, discusses the diagnosis and prognosis of patients with locally advanced cutaneous squamous cell carcinoma.
FDA Approves Cosibelimab for Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Accelerated Approval Sought for RP1 Plus Nivolumab in Advanced Melanoma
FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma
The OncFive: Top Oncology Articles for the Week of 11/10
RP1 Plus Nivolumab Is Active, Safe in Advanced Melanoma After Progression on Anti–PD-1 Therapy
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS